On Friday, the FDA approved BridgeBio Pharma ... Also Read: BridgeBio Pharma’s Acoramidis Shows Competitive Edge Against Pfizer’s Tafamidisa In Lucrative But Competitive ATTR-CM Market ...

FDA approves BridgeBio's Attruby for ... Also Read: BridgeBio Pharma’s Acoramidis Shows Competitive Edge Against Pfizer’s Tafamidisa In Lucrative But Competitive ATTR-CM Market Attruby is ...

Nov 22 (Reuters) - (This Nov. 22 story has been corrected to fix the list price of Pfizer's drug to about $268,000, not $225,000, in paragraph 3) The oral drug, branded as Attruby, was approved to ...

The study achieved its primary endpoint — treatment with the drug ... Pfizer this year in the hemophilia space. Earlier in July, the FDA approved Durveqtix (fidanacogene elaparvovec), the ...

Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization for Hympavzi (marstacimab) to treat certain hemophilia patients. With this nod, the once-weekly ...

First, the Big Pharma scored an FDA approval for its hemophilia B gene therapy Beqvez. But of greater concern for Centessa was the approval granted last month to Hympavzi, Pfizer’s anti-tissue ...

The study achieved its primary endpoint — treatment with the drug ... Pfizer have lost 13.4% against the industry’s 3.1% growth. The latest decision marks the second EC approval for Pfizer this year ...

The drug, marketed under the name Attruby, was proven under testing to postpone the hospitalizations for people living with the disease. STORY HIGHLIGHTS FDA approved BridgeBio's new heart disease ...

The company also has a partnership with AstraZeneca's unit, Alexion, for marketing the drug in Japan. Pfizer's lower-dose version of tafamidis, sold under the brand Vyndamax, has a recommended ...